BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 29143892)

  • 1. Update in the Therapy of Advanced Neuroendocrine Tumors.
    Uri I; Avniel-Polak S; Gross DJ; Grozinsky-Glasberg S
    Curr Treat Options Oncol; 2017 Nov; 18(12):72. PubMed ID: 29143892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Phan AT; Kunz PL; Reidy-Lagunes DL
    Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Uri I; Grozinsky-Glasberg S
    Clin Diabetes Endocrinol; 2018; 4():16. PubMed ID: 30009041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
    Flaum N; Valle JW; Mansoor W; McNamara MG
    Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
    Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
    BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
    Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.
    Yordanova A; Wicharz MM; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Fimmers R; Essler M; Ahmadzadehfar H
    Clin Cancer Res; 2018 Oct; 24(19):4672-4679. PubMed ID: 29950352
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
    Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Chandrasekharan C
    Surg Oncol Clin N Am; 2020 Apr; 29(2):293-316. PubMed ID: 32151362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
    J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium.
    Iyer R; Phan AT; Boudreaux JP
    Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):1-24. PubMed ID: 28654022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
    Barrett JR; Rendell V; Pokrzywa C; Lopez-Aguiar AG; Cannon J; Poultsides GA; Rocha F; Crown A; Beal E; Michael Pawlik T; Fields R; Panni RZ; Smith P; Idrees K; Cho C; Beems M; Maithel S; Weber S; Erik Abbott D
    J Surg Oncol; 2020 Jun; 121(7):1067-1073. PubMed ID: 32153032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
    Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
    Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors.
    Chow Z; Johnson J; Chauhan A; Izumi T; Cavnar M; Weiss H; Townsend CM; Anthony L; Wasilchenko C; Melton ML; Schrader J; Evers BM; Rychahou P
    Cells; 2021 May; 10(5):. PubMed ID: 34065268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances.
    Mohamed A; Strosberg JR
    J Nucl Med; 2019 Jun; 60(6):721-727. PubMed ID: 30737297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy for advanced pancreatic neuroendocrine tumors.
    Kulke MH
    Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors.
    Partelli S; Maurizi A; Tamburrino D; Baldoni A; Polenta V; Crippa S; Falconi M
    Eur J Endocrinol; 2014 Oct; 171(4):R153-62. PubMed ID: 24920289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.